Scholarlink

<p>Clinical interventions for adverse pregnancy outcomes (APOs, 1 in 5 pregnancies) are most effective when administered early ( &lt; 16–28 weeks), however risk-stratification in this window remains challenging. Here we review the main classes of biomarkers (proteins, nucleic acids, bacteria and biometabolites) showing high and early predictive value for the most prevalent APOs (preeclampsia, preterm birth, small for gestational age), and recent technological advances to develop non-invasive prenatal tests for these APOs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Emerging biomarkers and diagnostic tools for the early prediction of adverse prenatal outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Marc Soler,
  • Brenna Parke,
  • Sung Hye Kim,
  • Vasso Terzidou,
  • Sylvain Ladame

摘要

Clinical interventions for adverse pregnancy outcomes (APOs, 1 in 5 pregnancies) are most effective when administered early ( < 16–28 weeks), however risk-stratification in this window remains challenging. Here we review the main classes of biomarkers (proteins, nucleic acids, bacteria and biometabolites) showing high and early predictive value for the most prevalent APOs (preeclampsia, preterm birth, small for gestational age), and recent technological advances to develop non-invasive prenatal tests for these APOs.